Autoimmune Blistering Disease Management and Treatment

Autoimmune blistering diseases encompass a group of disorders characterised by pathogenic autoantibodies against structural proteins in the skin and mucous membranes, notably desmogleins within desmosomes. Clinical management has traditionally relied on high-dose systemic corticosteroids combined with broad-spectrum immunosuppressants to control acute flares and achieve remission. In recent years, therapy has shifted towards targeted immunomodulation, aiming to reduce side-effects associated with prolonged steroid use. Monoclonal antibodies that deplete B cells, such as anti-CD20 agents, have become first-line treatments, offering improved remission rates and faster tapering of corticosteroids. Emerging approaches now seek to stabilise epidermal adhesion directly, intervene in key signalling cascades, and harness engineered cellular therapies to selectively eliminate autoreactive lymphocytes. This integrated strategy promises more durable remissions, minimised toxicity and a move towards personalised, steroid-sparing regimens.

Research from Nature Portfolio

Recent studies have demonstrated that apremilast, a phosphodiesterase 4 inhibitor licensed for psoriasis, can directly reinforce keratinocyte cohesion in models of pemphigus vulgaris. Through ex vivo human epidermal cultures, in vitro keratinocyte assays and mouse experiments, apremilast was shown to prevent autoantibody-induced blistering by promoting phosphorylation of plakoglobin and assembly of desmoplakin into desmosomal plaques. These findings uncover a novel mechanism of desmosome regulation and suggest a therapeutic role for non-immunosuppressive agents that fortify cell–cell adhesion alongside standard immunotherapy.

Autoimmune Blistering Disease Management and Treatment publication trend

The graph below shows the total number of articles in autoimmune blistering disease management and treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Desmosome: A specialised intercellular junction that anchors keratin intermediate filaments and provides mechanical strength to the epidermis.

Desmoglein: A cadherin family adhesion protein component of desmosomes targeted by autoantibodies in pemphigus.

Acantholysis: Loss of keratinocyte cohesion resulting in intraepidermal blistering.

Phosphodiesterase 4 inhibitor: A compound that elevates intracellular cyclic AMP levels, modulating inflammatory signalling.

B-cell depletion therapy: Treatment that selectively removes or suppresses B lymphocytes, commonly via anti-CD20 monoclonal antibodies.

Chimeric antigen receptor (CAR) T-cell: A genetically engineered T cell bearing an antigen-specific receptor to target pathogenic B cells.

Autoantibody: An antibody produced by the immune system that recognises and binds to self-antigens, causing tissue damage.

References

1. Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus. Nature Communications (2023).
2. Immunostimulatory effects of Toll‐like receptor ligands as adjuvants in establishing a novel mouse model for pemphigus vulgaris. Clinical and Translational Medicine (2024).
3. Pemphigus: Current and Future Therapeutic Strategies. Frontiers in Immunology (2019).